About VBI Vaccines (TSE:VBV)
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.
Industry, Sector and Symbol
Trailing P/E Ratio-5.16483516483517
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-59.42%
Return on Assets-43.57%
VBI Vaccines (TSE:VBV) Frequently Asked Questions
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VBV."
When will VBI Vaccines make its next earnings announcement?
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Sherritt International (S), Cardinal Energy (CJ), Sirius XM Canada (XSR), Medical Facilities (DR), Dirtt Environmental Solutions (DRT), Sulliden Gold (SUE), Alterra Power (AXY), Sabina Gold & Silver (SBB), Callidus Capital (CBL), Stornoway Diamond (SWY), Morguard North American Residential REIT (MRG.UN), Bonterra Energy (BNE), Gluskin Sheff + Associates (GS), Crocotta Energy (CTA), Slate Office REIT (SOT.UN), Dhx Media Ltd Class B (DHX.B), Wajax (WJX) and Perseus Mining (PRU).
Who are VBI Vaccines' key executives?
VBI Vaccines' management team includes the folowing people:
- Steven D. Rubin, Chairman of the Board
- Curtis A. Lockshin Ph.D., Chief Executive Officer, Director (Age 56)
- Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller (Age 52)
- Shayla Forster, Corporate Secretary
- Dmitry Genkin, Director
- Kate Inman, Director
- Tomer Kariv, Director (Age 57)
- Adam Logal, Director
- David S. Rector, Additional Independent Director (Age 70)
How do I buy VBI Vaccines stock?
Shares of VBI Vaccines and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBI Vaccines stock can currently be purchased for approximately C$4.70.
How big of a company is VBI Vaccines?
VBI Vaccines has a market capitalization of C$239.53 million.
How can I contact VBI Vaccines?
VBI Vaccines' mailing address is 222 3rd St Ste 2241, CAMBRIDGE, MA 02142-1259, United States. The company can be reached via phone at +1-617-8303031.
MarketBeat Community Rating for VBI Vaccines (VBV)MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
VBI Vaccines (TSE:VBV) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
VBI Vaccines (TSE:VBV) Earnings History and Estimates Chart
VBI Vaccines (TSE VBV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/23/2018|| || || || || || || || |
VBI Vaccines (TSE:VBV) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for VBI Vaccines (TSE:VBV)
No dividend announcements for this company have been tracked by MarketBeat.com
VBI Vaccines (TSE VBV) Insider Trading and Institutional Ownership History
VBI Vaccines (TSE VBV) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/12/2017||Jeffrey Royston Baxter||Director||Buy||4,609||C$3.88||C$17,882.92|
|11/28/2017||Jeffrey Royston Baxter||Director||Buy||15,000||C$4.75||C$71,250.00|
|8/21/2017||Jeffrey Royston Baxter||Director||Buy||10,000||C$3.22||C$32,200.00|
VBI Vaccines (TSE VBV) News Headlines
|VBI Vaccines (VBIV) Announces Exit of Sam Chawla and Ran Nussbaum from Board|
www.streetinsider.com - January 27 at 9:29 AM
|VBI Vaccines Announces Changes to its Board of Directors|
finance.yahoo.com - January 26 at 4:27 PM
|VBI Vaccines, Inc. breached its 50 day moving average in a Bullish Manner : VBV-CA : January 1, 2018|
finance.yahoo.com - January 1 at 8:12 AM
|VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine|
finance.yahoo.com - December 19 at 8:08 AM
|Jeffrey Royston Baxter Buys 4,609 Shares of VBI Vaccines Inc (VBV) Stock|
www.americanbankingnews.com - December 13 at 10:20 PM
|VBI Vaccines, Inc. breached its 50 day moving average in a Bearish Manner : VBV-CA : December 12, 2017|
finance.yahoo.com - December 12 at 7:18 PM
|VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference|
finance.yahoo.com - December 12 at 8:06 AM
|VBI Vaccines, Inc. :VBV-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017|
finance.yahoo.com - November 30 at 4:41 PM
|ETFs with exposure to VBI Vaccines, Inc. : November 27, 2017|
finance.yahoo.com - November 30 at 4:41 PM
|VBI Vaccines Inc. (VBV) Director Buys C$71,250.00 in Stock|
www.americanbankingnews.com - November 29 at 10:40 PM
|Insider Buying: VBI Vaccines Inc (VBV) Director Acquires 10,000 Shares of Stock|
www.americanbankingnews.com - August 23 at 8:50 PM
VBI Vaccines (TSE:VBV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
VBI Vaccines (TSE VBV) Stock Chart for Saturday, February, 17, 2018